Search

Displaying results 2681 - 2690 of 4575 in total
  1. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated patients.

  2. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. … It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.

  3. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    Chlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.

  4. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  5. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    Pemivibart (Pemgarda) is a human IgG1 monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain. It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COV...

  6. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    It was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.

  7. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.

  8. Drug

    Adenosine phosphate

    go.drugbank.com/drugs/DB00131
    ApprovedInvestigationalNutraceuticalWithdrawn

    Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]

  9. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126]

  10. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.